SAbR Plus Ipilimumab Plus Nivolumab in Metastatic Melanoma Patients
A one-arm, single center phase 2 trial of SAbR plus ipilimumab plus nivolumab in advanced metastatic melanoma patients
Melanoma|Metastatic Melanoma
RADIATION: SAbR|DRUG: Ipilimumab|DRUG: Nivolumab
Change of tumor size from baseline to follow up, treatment response rate-RR based on RECISTv1.1, at 12, 24, 36 weeks
disease control rate, disease control rate defined as response plus stable disease based on RECISTv1.1, at 12, 24, 36 weeks|Number of treatment-related adverse events, Number of participants with treatment-related adverse events as assessed by CTCAE v4.0, 2 years|programmed death ligand-1 (PD-L1) expression, compare tumor PD-L1 expression at 3 time points, baseline, cycle 1 Day 1, and week 15
SAbR/GRID plus ipilimumab 3mg/kg IV q3wk x 4 plus nivolumab 1 mg/kg IV q3wk x 4, followed by nivolumab 240 mg IV q 2wk until progression or intolerable toxicity